The New 4-O-Methylhonokiol Analog GS12021 Inhibits Inflammation and Macrophage Chemotaxis: Role of AMP-Activated Protein Kinase α Activation

Sora Kim‡, Sun-O Ka‡, Youngyi Lee¹, Byung-Hyun Park², Xiang Fei³, Jae-Kyung Jung⁴, Seung-Yong Seo³*, Eun Ju Bae¹*

¹ College of Pharmacy, Woosuk University, Wanju-gun, Jeollabuk-do, Korea, ² Department of Biochemistry, Medical School and Diabetes Research Center, Chonbuk National University, Jeonju, Jeollabuk-do, Korea, ³ College of Pharmacy, Gachon University, Incheon, Korea, ⁴ College of Pharmacy, Chungbuk National University, Cheongju, Korea

‡ These authors contributed equally to this work.
* syseo@gachon.ac.kr (SYS); ejbae@woosuk.ac.kr (EJB)

Abstract

Preventing pathologic tissue inflammation is key to treating obesity-induced insulin resistance and type 2 diabetes. Previously, we synthesized a series of methylhonokiol analogs and reported that compounds with a carbamate structure had inhibitory function against cyclooxygenase-2 in a cell-free enzyme assay. However, whether these compounds could inhibit the expression of inflammatory genes in macrophages has not been investigated. Here, we found that a new 4-O-methylhonokiol analog, 3',5-diallyl-4'-methoxy-[1,1'-biphenyl]-2-yl morpholine-4-carboxylate (GS12021) inhibited LPS- or TNFα-stimulated inflammation in macrophages and adipocytes, respectively. LPS-induced phosphorylation of nuclear factor-kappa B (NF-κB)/p65 was significantly decreased, whereas NF-κB luciferase activities were slightly inhibited, by GS12021 treatment in RAW 264.7 cells. Either mitogen-activated protein kinase phosphorylation or AP-1 luciferase activity was not altered by GS12021. GS12021 increased the phosphorylation of AMP-activated protein kinase (AMPK) α and the expression of sirtuin (SIRT) 1. Inhibition of mRNA expression of inflammatory genes by GS12021 was abolished in AMPKα1-knockdown cells, but not in SIRT1 knockout cells, demonstrating that GS12021 exerts anti-inflammatory effects through AMPKα activation. The transwell migration assay results showed that GS12021 treatment of macrophages prevented the cell migration promoted by incubation with conditioned medium obtained from adipocytes. GS12021 suppression of p65 phosphorylation and macrophage chemotaxis were preserved in AMPKα1-knockdown cells, indicating AMPK is not required for these functions of GS12021. Identification of this novel methylhonokiol analog could enable studies of the structure-activity relationship of this class of compounds and further evaluation of its in vivo potential for the treatment of insulin-resistant states and other chronic inflammatory diseases.
INTRODUCTION

Metabolic syndrome (including hyperlipidemia, fatty liver, and obesity-associated insulin resistance and type-2 diabetes mellitus (T2DM)) is an important problem worldwide. It is well established that adipose tissue is a mediator of inflammation and innate immunity [1, 2]. Therefore, strategies to curb inflammation of adipose tissue as therapy to treat metabolic syndrome have become popular.

In response to increased intake of energy, adipose tissue increases in mass due to hypertrophy (increase in cell size) and hyperplasia (increase in cell numbers). Expanded adipose tissue produces and secretes adipokines/chemokines such as tumor necrosis factor (TNF) α, interleukin (IL)-6, IL-1β, and monocyte chemoattractant protein-1 (MCP)-1. Pro-inflammatory cytokines secreted from adipose tissue act in an endocrine manner on peripheral tissues (e.g., skeletal muscle) and the liver, as well as on adipose tissue itself in an autocrine manner to disturb normal insulin signaling, thereby inducing insulin resistance. In adipose tissue, infiltrating macrophages and other immune cells as well as adipocytes are responsible for tissue inflammation. Infiltration of immune cells to adipose tissue is mediated primarily by chemokines secreted by adipose tissue itself. In particular, MCP-1 acts as a major chemokine to further recruit monocytes/macrophages into adipose tissue, leading to aggravation of inflammation in adipose tissue and systemic insulin resistance [3].

The phenolic neolignans honokiol and 4-O-methylhonokiol are the biologically active components of Magnolia officinalis. They have been shown to have anticancer, antifibrosis, antithrombotic, and anti-inflammatory effects in various cell types and animal models [4–10]. Recent studies have shown that supplementation with honokiol or 4-O-methylhonokiol ameliorates accumulation of body fat, insulin resistance, and adipose inflammation in high-fat-fed mice [11, 12]. The findings that honokiol and 4-O-methylhonokiol exert anti-inflammatory effects in vitro and that they prevent obesity, inflammation in adipose tissue, and insulin resistance in mice support the notion that macrophage-mediated inflammation of adipose tissue is a key mediator of insulin resistance and T2DM.

Previously, we designed and synthesized a series of derivatives of 4-O-methylhonokiol (including derivatives of aryl carbamate) to increase its biological activity and metabolic stability and reported their inhibitory activities against cyclooxygenase (COX)-2 enzyme in a cell-free system [13]. Among the 4-O-methylhonokiol analogs we tested, carbamate compounds showed more potent inhibitory activity against COX-2 than the selective COX-2 inhibitor celecoxib as well as the natural product honokiol. We also ascertained if carbamate compounds could prevent nitric oxide (NO) production in lipopolysaccharide (LPS)-stimulated macrophages, but few compounds were found to inhibit NO production at non-cytotoxic concentrations. However, whether 4-O-methylhonokiol analogs can inhibit the expression of pro-inflammatory genes and cytokine production in macrophages remains unknown.

Thus, in the present study, we hypothesized that 4-O-methylhonokiol analogs could inhibit the LPS-stimulated inflammatory response, and we examined the influences of these analogs on MCP-1 production and macrophage chemotaxis as well. We also investigated the molecular mechanism of action of a new 4-O-methylhonokiol analog, GS12021, which was chosen as a representative compound with anti-inflammatory and chemotaxis-inhibitory activities.

MATERIALS AND METHODS

Synthesis of 3’,5-diallyl-4’-methoxy-[1,1’-biphenyl]-2-yl morpholine-4-carboxylate (GS12021)

Triphosgene (89 mg, 0.3 mmol) maintained at 0°C was added to a CH2Cl2 solution (1 mL) of 4-O-methylhonokiol (42 mg, 0.15 mmol) and pyridine (80 mg, 1 mmol). After stirring for 2 h
at ambient temperature, morpholine (26 mg, 0.3 mmol) was added to the reaction mixture. After stirring for 12 h at ambient temperature, the reaction mixture was diluted with CH₂Cl₂, washed with aqueous NH₄Cl solution and brine, dried over MgSO₄, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate:hexanes = 1:2) to afford the morpholinylcarbamate (GS12021) (40 mg, 68%).

1H-NMR (400 MHz, CDCl₃) δ 7.23 (dd, 1H, J = 8.4 and 1.8 Hz), 7.18 (d, 1H, J = 1.2 Hz), 7.16 (d, 1H, J = 1.8 Hz), 7.15 (d, 1H, J = 8.4 and 1.8 Hz), 7.10 (d, 1H, J = 7.8 Hz), 6.88 (d, 1H, J = 8.4 Hz), 6.02–5.95 (m, 2H), 5.12–5.03 (m, 4H), 3.86 (s, 3H), 3.61 and 3.54 (two bs, 4H), 3.44 (bs, 4H), 3.41–3.39 (m, 4H); IR (neat) 2963, 2916, 2857, 1720, 1241, 1198 cm⁻¹; 13C-NMR (150 MHz, CDCl₃) δ 156.7, 153.6, 146.4, 137.6, 137.1, 136.7, 134.5, 130.8, 130.4, 130.1, 128.1, 127.9, 123.0, 116.0, 115.5, 110.0, 66.6, 55.5, 44.7, 39.6, 34.4; LRMS (ESI) m/z 394 (M+H⁺) and 416 (M+Na⁺). The synthetic procedures for the remaining compounds (c1~c9) can be found in S1 File and Figure A in S1 File.

Cell cultures

A murine macrophage cell line RAW 264.7 was maintained in growth medium containing Dulbecco’s modified Eagle’s medium (DMEM), 10% fetal bovine serum (FBS), 50 U/mL penicillin and 50 μg/mL streptomycin at 37°C in a humidified atmosphere with 5% CO₂. Peritoneal macrophages were isolated from wild type or myeloid-specific SIRT1 knockout mice by peritoneal lavage 3 days after injection of 3 mL of 3% thioglycolate (Difco, Sparks, MD, USA) and plated in 12-well plates at 2 × 10⁵ cells/well. All experimental procedures were approved by the Institutional Animal Care and Use Committee of Chonbuk National University. Murine 3T3-L1 preadipocyte cells were maintained in growth medium containing DMEM, 10% FBS, 50 U/mL penicillin and 50 μg/mL streptomycin at 37°C in a humidified atmosphere with 10% CO₂ and induced to differentiate as described previously [14].

Cell viability

Cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells in 96-well culture plates were incubated with compounds at 20 μM or 40 μM in the presence of FBS for 24 h. After incubation, 20 μL of MTT (0.5 mg/mL in PBS) was added to each well and the cells were incubated further for 3 h at 37°C. Formation of the violet precipitate formazan was monitored at 560 nm and 670 nm with a spectrophotometer.

Measurement of NO levels

Production of NO was estimated by measuring the amount of nitrite (a stable metabolite of NO) using the Griess reagent, as described previously. Briefly, cells were pretreated with GS12021 or honokiol for 1 h before the addition of LPS. After 24 h, aliquots of culture supernatants were mixed with an equal volume of a modified Griess reagent comprising a 1:1 mixture of 1% sulfanilamide in 30% acetic acid and 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride in 60% acetic acid, at room temperature for 5 min, and absorbance was measured at 540 nm using a spectrophotometer.

Cell lysis and western blot analyses

Whole-cell lysate preparation and western blot analyses were performed as described previously [14]. Briefly, cells were lysed in buffer containing 10 mM Tris-HCl (pH 7.1), 100 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% Triton X-100, 0.5% Nonidet P-40, 1 mM dithiothreitol and...
0.5 mM phenylmethylsulfonyl fluoride, supplemented with proteinase and phosphatase inhibitors. Protein concentrations in cell lysates were determined using a Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA). Aliquots of lysates underwent electrophoresis in 6–10% sodium dodecyl sulfate-polyacrylamide gels (20 μg of protein/lane). Separated proteins were transferred onto nitrocellulose membranes (GE Healthcare, Piscataway, NJ, USA). Membranes were blocked with 0.4% skimmed milk in TBS-1% Tween 20 and incubated with primary antibodies, followed by incubation with secondary antibodies. Immunoreactive proteins were visualized using an ECL Chemiluminescence Detection kit (Amersham Biosciences, Buckinghamshire, UK). Images were obtained using a ChemiDoc XRS+ system (Bio-Rad). The primary antibodies used were as follows: inducible nitric oxide synthase (iNOS) from BD Biosciences (Palo Alto, CA, USA); β-tubulin (#PA1–16947) from Thermo Scientific (Waltham, MA, USA); COX-2 (sc-1745) and inhibitor of kappa B alpha (IκBα; sc-371), from Santa Cruz Biotechnology (Santa Cruz, CA, USA); p-p65 (Ser536, ab76302), p-p38 (#4631), phosphorylated extracellular signal-regulated kinase (p-ERK; #9101), p-Akt (#92759), phosphorylated AMP protein kinase (p-AMPK; #2535), AMPKα (#27153), p-acetyl CoA carboxylase (p-ACC; #36615), and ACC (#3662) from Cell Signaling Technology (Beverly, MA, USA).

RNA isolation and real-time reverse-transcription polymerase chain reaction (RT-qPCR)

Total RNA was extracted from cells or adipose tissue with TRIzol reagent (Invitrogen Carlsbad, CA, USA). Total RNA (2 μg) was reverse-transcribed using random primers (Promega, Madison, WI, USA). RT-qPCR was performed as described previously using an ABI7000 and Stratagene3000 MXP PCR cycler with Sybr Green Detection System 6. mRNA expression of all the genes tested was normalized to Rps3 expression. All the RT-qPCR experiments were replicated three times with duplicate analysis. Primer sequences (sense and antisense, respectively) were as follows: Nos2, 5′-AATCTTTGAGCGAGTTGTGG-3′ and 5′-CAGGAAGTAGGTGAGGGCTTG-3′; Il6, 5′-CCAGAGATACAAAGAAATGATGG-3′ and 5′-ACTCCAGAGACGAGGAAAT-3′; Mcp1/Ccl2, 5′-TCTGGACCCATTCCTTCTTG-3′ and 5′-AGGTCCCTGTCATGCTTCTG-3′; Tnfα, 5′-GCCAACACGGCTTCTGCTC-3′ and 5′-GCGTGTAGTGTTGGGTGAGG-3′; COX2, 5′-AAAGACTCTGGCTACACCC-3′ and 5′-ATGCTACCTTTGGCAGGTCA-3′; Il1b, 5′-AAATACCTGTGCGCTTGGGC-3′ and 5′-CTTGGATCCACACTCTCCAG-3′.

RNA interference

Duplexes of small interfering RNA (siRNA), targeting AMPKα1 mRNA (target sequences: 5′-CGGGAUCCAUCAGCAACUA-3′ for sense and 5′-UAGUUGCUAGUGAUCGC-3′ for antisense) and a negative control (scrambled sequence) were purchased from Dharmacon Research (Lafayette, CO, USA). We transfected 2 × 10⁶ RAW 264.7 cells with 0.5 nmol of siRNA oligonucleotides to mouse AMPKα1 or scrambled control siRNA using Lipofectamine 2000 (Invitrogen). siRNA-transfected cells were incubated for 24 h at 37°C before assays.

Transient transfection and luciferase reporter assay

RAW 264.7 cells were seeded on 24-well plates and incubated for 24 h. For reporter gene assays, cells were transfected with 200 ng of nuclear factor-kappa B (NF-κB)-luciferase (luc) or AP-1 luciferase (Stratagene, La Jolla, CA, USA), and 20 ng of pRL-TK (Promega) using Lipofectamine 2000 (Invitrogen). After 24 h of incubation, cells were treated with vehicle or GS12021 1 h before LPS (10 ng/mL) exposure and incubated for a further 24 h. Protein was extracted from cells using passive lysis buffer (Promega), and luciferase activity was measured.
using a Dual Luciferase Reporter assay (Promega) from Lumat LB 9507 (Berthold, Bad Wildbad, Germany).

**Macrophage chemotaxis assay**

For the preparation of adipocyte-conditioned medium (CM), mature 3T3-L1 adipocytes (> 90% of cells showing large lipid droplets when observed under a microscope) were used. At day 10 of differentiation, culture media were changed and the cells were incubated further with migration media (serum-free, 0.2% endotoxin-free, and free fatty acid-free bovine serum albumin in DMEM) for 48 h. The media collected were centrifuged at 15,000 x g for 10 min to remove cell debris, and the supernatants collected were aliquoted and frozen at -70°C until use for the chemotaxis assay. For migration per se, 5 x 10^5 RAW 264.7 cells suspended in migration media were placed in the upper chamber of a polycarbonate filter with a pore size of 8 μm (24-transwell format; Corning, Lowell, MA, USA), whereas adipocyte-CM was placed in the lower chamber. After 3 h of migration, cells were fixed in formalin and stained with 0.1% crystal violet. Macrophages that had remained in the upper chamber were removed by wiping the filters with cotton tips. Macrophages found on the bottom of filters were counted as cells that had carried out chemotaxis. Cells were quantified from 5 fields/condition; each condition was carried out in triplicate.

**Statistical analyses**

Data are provided as mean ± SEM values. The significance of differences between treatment groups was determined by one-way ANOVA with the Turkey’s post-hoc test using GraphPad Prism v4.0 (GraphPad, San Diego, CA, USA). P < 0.05 or 0.01 was considered significant.

**RESULTS**

4-O-Methylhonokiol analogs suppressed LPS-stimulated expression of iNOS and COX-2

We synthesized a series of honokiol derivatives (including methylhonokiol analogs) according to the methods described in the Methods and Materials section and S1 File. The chemical structures of the compounds are shown in Fig. 1 and Figure A in S1 File. Previously, honokiol was reported to have pro-apoptotic or anti-proliferative effects in cancer cells. Hence, we first determined the effects of compounds on the viability of RAW 264.7 cells. Cells were incubated with the agents (20 μM or 40 μM) for 24 h in the presence of serum and cell viability determined by the MTT assay. Treatment of cells with each of the compounds c7, c8, or c9 at 20 μM reduced cell viability markedly (Fig. 2A). When cells were treated with 40 μM of each compound, cell viability was not affected except for honokiol and c5 (which reduced cell viability significantly). Therefore, subsequent experiments were conducted at 20 μM of each compound unless stated otherwise.

Next, we examined the effects of agents on LPS-induced expression of iNOS and COX-2 because honokiol has been reported to inhibit expression of pro-inflammatory genes. RAW 264.7 cells were pretreated with 20 μM of honokiol or its analogs 1 h before treatment with LPS (10 ng/mL) for 24 h. The protein level was measured by western blotting (representative blots were shown in Fig. 2B). As expected, honokiol treatment of RAW 264.7 cells resulted in inhibition of the expression of iNOS and COX-2. More importantly, one of the methylhonokiol analogs, GS12021, which has a novel structure, inhibited expression of iNOS and COX-2 with a potency equal to that seen with honokiol. Compounds between c1 and c7 did not affect expression of these genes. The effects of honokiol and GS12021 on the expression of iNOS and COX-2 as
well as nitrite production are shown in Fig. 2C and D. Taken together, our observations indicated that GS12021 was as efficacious as honokiol in preventing gene expression of iNOS and COX-2 and that GS12021 was not cytotoxic, whereas honokiol showed cytotoxicity at 40 μM. Therefore, we chose GS12021 as a representative methylhonokiol analog for further study.

GS12021 inhibits the expression of pro-inflammatory genes and cytokines/chemokine secretion in RAW 264.7 cells

We observed that GS12021 significantly suppressed expression of iNOS and COX-2 proteins; therefore, we analyzed whether the inhibition was dependent upon concentration. GS12021 significantly inhibited the LPS-stimulated induction of iNOS and COX-2 at 10, 20, and 40 μM in a concentration-dependent manner (Fig. 3A). Consistently, LPS-stimulated NO production was suppressed by pretreatment with GS12021 (Fig. 3B). To confirm the anti-inflammatory effect of GS12021 in macrophages, we measured the mRNA level of inflammatory genes/chemokines in GS12021-treated cells by RT-qPCR. mRNA levels of TNFα, iNOS, MCP-1, COX-2, IL-1β and IL-6 were strongly induced by LPS treatment, whereas pretreatment with GS12021 markedly blocked their expression (Fig. 3C). Secretion of TNFα and IL-6, as demonstrated by the enzyme-linked immunosorbent assay (ELISA), was also suppressed by GS12021 pretreatment (Fig. 3D). Secretion of MCP-1 (a representative chemokine essential for macrophage chemotaxis) was also reduced significantly by GS12021 pretreatment, implying that GS12021 may exhibit anti-chemotactic effects as well as anti-inflammatory effects in macrophages.

GS12021 inhibits macrophage chemotaxis

We performed an in vitro chemotaxis assay to investigate the functional consequences of the inhibitory activity of GS12021 on macrophage inflammation [14,15]. RAW 264.7 macrophages were treated with GS12021 for 3 h and then seeded on the upper insert well of a chemotaxis chamber and incubated for 3 h in the presence of DMEM or adipocyte-CM in the lower
A 3-h migration was chosen because it provides optimal results in the macrophage chemotaxis assay, as described previously [15]. Adipocyte-CM significantly stimulated macrophage chemotaxis in comparison with DMEM (Fig. 4). However, exposure of macrophages to GS12021 abrogated cell migration in response to adipocyte-CM, indicating that GS12021 inhibited the ability of macrophages to migrate toward adipocyte-derived chemoattractants.

GS12021 inhibits an NF-κB/p65 phosphorylation in RAW 264.7 cells

Studies have reported that honokiol inhibits inflammatory responses through blockade of NF-κB signaling [4,10]. To elucidate the anti-inflammatory mechanism of action of the newly identified methylhonokiol analog GS12021, we examined the effect of GS12021 on signaling pathways activated by LPS in RAW 264.7 cells. I kappa B kinase (IKK) phosphorylation and

---

Fig 2. Effects of treatment with a honokiol analog on cell viability, expression of iNOS and COX-2, and production of NO in RAW 264.7 cells. (A) RAW 264.7 cells were incubated with each compound (20 μM or 40 μM) in the presence of serum for 24 h. Cell viability was determined by the MTT assay. (B)-(C) Cells were pretreated with 20 μM of compounds 1 h before LPS treatment (10 ng/mL) for 24 h. The protein level was measured by western blotting. The experiments were repeated at least three times and representative blots (B) and quantification data (C) are shown. β-tubulin was used as a loading control. (D) Nitrite content. Nitrite levels were measured by spectrophotometric means with Griess reagent using supernatant media obtained from the cells in (B). HK, honokiol; GS, GS12021; c1–c9, arbitrary names for the synthetic honokiol analogs. Data are provided as mean ± SEM values. *P < 0.05, **P < 0.01 versus CON; ^P < 0.05, ^^P < 0.01 versus LPS alone treatment.

doi:10.1371/journal.pone.0117120.g002
**Fig 3. Anti-inflammatory effect of GS12021 in RAW 264.7 cells.** (A) Concentration-dependent effect of GS12021 on expression of iNOS and COX-2. Representative western blot images and quantification data are shown. Cells were pretreated with the indicated concentrations of GS12021 1 h before LPS treatment (10 ng/mL) for 24 h. (B) Nitrite production in cells from (A). (C) mRNA expression of inflammatory genes/cytokines. Cells were treated with agents for 6 h and RT-qPCR was performed. (D) Cytokine levels in supernatant media from cells treated with LPS ± GS12021 for 6 h (TNFα) or 24 h (IL-6 and MCP-1). All the experiments were repeated at least three times and the data are provided as mean ± SEM values. **P < 0.01 versus CON; #P < 0.05, ##P < 0.01 versus LPS treatment alone.

doi:10.1371/journal.pone.0117120.g003
IkBα degradation were enhanced by LPS but were not changed by GS12021 pretreatment (Fig. 5A). Activation of the NF-κB component RelA/p65 requires post-translational modifications; therefore, we examined the phosphorylation of p65. Interestingly, although GS12021 pretreatment did not cause any alteration in IKK phosphorylation and IkBα degradation stimulated by LPS, GS12021 pretreatment resulted in significant blockade of phosphorylation of p65 (Fig. 5A). Moreover, the phosphorylations of JNK, ERK, p38 MAPK, Akt, c-Jun and S6 protein, all of which have been shown to regulate inflammatory responses, were not inhibited by GS12021 pretreatment (Fig. 5B).

Considering our finding that GS12021 attenuates NF-κB phosphorylation, we examined the influence of GS12021 on NF-κB promoter activity using the NF-κB luciferase assay. In NF-κB luciferase plasmid-transfected RAW 264.7 cells, luciferase activity was stimulated by LPS treatment for 24 h but was decreased by pretreatment with GS12021 at 40 μM (Fig. 5C). The promoter activity of AP-1, another important regulator of inflammation, was not changed by GS12021.
treatment (Fig. 5D). Because the ability of GS12021 at 20 μM to inhibit NF-κB luciferase activity was mild even though the degree of inhibition of protein expression of iNOS was almost complete (Figs. 2B and 3A), we hypothesized that GS12021 may affect the stability of iNOS protein. Therefore, an additional study was conducted to ascertain if GS12021 treatment altered the stability of iNOS protein. RAW 264.7 cells were incubated with LPS for 6 h to induce iNOS expression with or without GS12021 (20 μM or 40 μM) pretreatment for 0.5 h and were then exposed to cycloheximide (5 μg/mL), an inhibitor of protein translation. Exposure of cells to cycloheximide for up to 4 h resulted in a gradual decrease in the iNOS protein level, which was not altered in the presence of GS12021 (Figure B in S1 File). Our observations indicate that GS12021 attenuated the expression of pro-inflammatory genes at the level of transcription and its regulation of transcription is at least in part associated with the inhibition of NF-κB/p65 phosphorylation.

**GS12021 activates an AMPKα signaling pathway in RAW 264.7 cells**

AMPKα is a cellular energy sensor protein and is known to modulate inflammation [16–18]. Honokiol is known to activate AMPKα in cancer cells to mediate its antitumor effect [19];
therefore, we examined the effects of GS12021 on AMPKα signaling to further explore its anti-inflammation mechanism in macrophages. LPS treatment in RAW 264.7 cells resulted in a decrease in AMPKα phosphorylation at 30 min and 60 min, which was in agreement with the finding that pro-inflammatory stimuli such as LPS can suppress AMPKα signaling [20]. However, GS12021 pretreatment increased AMPKα phosphorylation significantly (Fig. 6A).

Consistently, time-course experiments showed that GS12021 significantly increased phosphorylation of ACC (a downstream substrate of AMPKα) from 3 h up to 24 h, as well as AMPKα phosphorylation (Fig. 6B). AMPK activity is known to be regulated by nicotinamide adenine dinucleotide-dependent histone deacetylase sirtuin (SIRT)-1 as well as by upstream kinases such as liver kinase B 1 or calcium/calmodulin-dependent protein kinase kinase 1 [21]. Furthermore, SIRT1 has been reported to play a central part in the regulation of the pathogenesis of chronic inflammatory diseases [22]. Hence, we also examined SIRT1 expression after GS12021 treatment. Interestingly, SIRT1 expression was also increased by GS12021 treatment.
implying that AMPK activation and the stimulated SIRT1 expression might contribute to the anti-inflammatory effect of GS12021. The concentration-dependent effect of GS12021 on AMPK activation and SIRT1 is shown in Fig. 6C.

The anti-inflammatory effect of GS12021 is mediated by AMPKα but not by SIRT1

To investigate the causal relationships between AMPKα activation or SIRT1 expression and macrophage inflammation by GS12021, we examined GS12021 responses in AMPKα knockdown or SIRT1 knockout cells. AMPKα1 is the predominant AMPKα isoform expressed by macrophages [20]; therefore, we performed an siRNA interference study using siRNA targeting AMPKα1. After transient transfection of siRNA targeting AMPKα1 or control siRNA in RAW 264.7 cells, cells were treated with LPS for 6 h with or without GS12021. The level of AMPKα was reduced by transfection of AMPKα1 siRNA (Fig. 7A). As expected, GS12021 treatment significantly inhibited the LPS-induced expression of inflammatory genes such as iNOS, TNFα, and MCP-1/CCL2 in AMPKα1 knockdown macrophages. **P < 0.01 versus vehicle; *P < 0.05, ##P < 0.01 versus LPS alone. (C)-(D) The effect of AMPKα1 knockdown on the GS12021 suppression of p-p65 and the adipocyte CM-mediated macrophage chemotaxis. Representative microphotographs of cell migration are shown above the quantification results (N = 3). AU means arbitrary units. **P < 0.01 versus vehicle.

doi:10.1371/journal.pone.0117120.g007
activation, we employed the AMPKα-specific chemical inhibitor compound C. Treatment with compound C alone could completely inhibit the expression of inflammatory genes by LPS treatment (data not shown). Given that many researchers have demonstrated that AMPKα activation plays an anti-inflammatory role, the anti-inflammatory effect of compound C in macrophages was unexpected and merits further investigation. Next, we examined the effect of siRNA for AMPKα1 on GS12021-inhibition of p65 phosphorylation. As shown in Fig. 7C, GS12021 was able to inhibit LPS-induced p65 phosphorylation in AMPKα1 depleted cells. Moreover, GS12021 also inhibited adipocyte CM stimulated cell migration in AMPKα1 depleted macrophages (Fig. 7D). These results indicate that AMPK was not required for GS12021 to inhibit either p65 phosphorylation or macrophage chemotaxis, being in a clear contrast to the anti-inflammatory function of GS12021.

Next, we tested the effect of GS12021 in SIRT1 knockout macrophages. To obtain peritoneal macrophages, we used the thioglycollate-elicited peritoneal macrophage protocol described in detail in the Materials and Methods section in wild-type (WT) and myeloid-specific SIRT1 knockout mice. SIRT1 appeared to be dispensable for the inhibition of inflammation by GS12021 (Fig. 8). In addition, methylhonokiol has been shown to activate peroxisome proliferator-activated receptor (PPAR) γ [23] and PPARγ plays an important role in the suppression of inflammation; therefore, we conducted an experiment using the PPARγ antagonist GW9662. Pretreating cells with GW9662 (10 μM) for 30 min before incubating the cells with GS12021 and LPS for 6 h did not reverse the GS12021-induced inhibition of iNOS, TNFα and MCP-1 mRNA expression (data not shown). Our observations indicate that activation of SIRT1 or PPARγ is not involved in the anti-inflammatory function of GS12021.


Inhibition of inflammation is closely related to improvement of insulin resistance in diet-induced obesity. In view of the fact that adipose tissue inflammation in obesity results from the feed-forward inflammatory responses between adipocytes and macrophages, and to clearly determine the potential of GS12021 to curb obesity linked insulin resistance, we next examined whether GS12021 inhibits inflammation in adipocytes as in macrophages. Because the expression level of LPS receptor toll-like receptor 4 is very low in adipocytes, we treated cells with TNFα to induce inflammatory responses in adipocytes. As shown in Fig. 9, the mRNA expression of a series of inflammatory genes was promoted by TNFα treatment for 6 h in 3T3-L1 adipocytes but was blocked by GS12021 pretreatment, indicating an anti-inflammatory activity of GS12021 in adipocytes as well as in macrophages.

**GS12021 inhibits TNFα stimulated adipocyte inflammation**

Inhibition of inflammation is closely related to improvement of insulin resistance in diet-induced obesity. In view of the fact that adipose tissue inflammation in obesity results from the feed-forward inflammatory responses between adipocytes and macrophages, and to clearly determine the potential of GS12021 to curb obesity linked insulin resistance, we next examined whether GS12021 inhibits inflammation in adipocytes as in macrophages. Because the expression level of LPS receptor toll-like receptor 4 is very low in adipocytes, we treated cells with TNFα to induce inflammatory responses in adipocytes. As shown in Fig. 9, the mRNA expression of a series of inflammatory genes was promoted by TNFα treatment for 6 h in 3T3-L1 adipocytes but was blocked by GS12021 pretreatment, indicating an anti-inflammatory activity of GS12021 in adipocytes as well as in macrophages.
DISCUSSION

Pathological tissue inflammation is a key process that can elicit and precipitate various conditions, including obesity and T2DM. Obesity develops gradually, and expansion of adipose tissue occurs due to the hypertrophy and hyperplasia of adipocytes. Subsequent increases in the release of pro-inflammatory adipokines/chemokines such as TNF-α and MCP-1 as well as free fatty acids from adipocytes promote inflammation of adipose tissue and lead to insulin resistance in peripheral tissues. In particular, MCP-1, which is secreted from adipocytes and infiltrating macrophages in adipose tissue, acts as a major chemokine to further recruit monocytes/macrophages into adipose tissue, leading to aggravation of inflammation of adipose tissue.

Plasma levels of MCP-1 increase in sepsis and obesity in humans [24–26]. MCP-1 (also known as CCL2) is a member of the C-C chemokine family and a potent chemotactic factor for monocytes [27]. MCP-1 is produced by various cell types, and monocyte/macrophages are the major source of this chemokine. MCP-1 mediates its effects through its receptor CCR2 and regulates the migration and infiltration of immune cells, thereby serving as a mediator of tissue inflammation. In addition to its chemotactic activity for leukocytes, MCP-1 plays a part in the metastasis and angiogenesis of tumors. It also plays a role in modulation of the proliferation and apoptosis of and protein synthesis in cells. Thus, MCP-1 is a potential “intervention point” for the treatment of various inflammatory diseases, such as multiple sclerosis, rheumatoid arthritis, atherosclerosis, and insulin-resistant T2DM [3], [28–32].

We identified a new 4-O-methylhonokiol analog, GS12021, which has potent anti-inflammatory functions in macrophages without affecting cell viability at ≤ 40 μM (the maximal concentration that we tested). Considering that honokiol reduced cell viability at 40 μM and that the anti-inflammatory efficacy of GS12021 was equivalent to that of honokiol at lower concentrations, GS12021 could be a superior option to honokiol in the treatment of various inflammatory diseases. More importantly, we showed that GS12021 opposed not only the production of the major chemokine MCP-1 and pro-inflammatory cytokines but also macrophage chemotaxis toward adipocyte-CM. It is well established that prevention of macrophage chemotaxis into peripheral tissues (e.g., adipose tissue) is a major therapeutic approach against chronic inflammatory conditions such as obesity and T2DM, highlighting the therapeutic importance of the findings of the present study.

In addition, we found that GS12021 inhibits LPS-stimulated NF-κB/p65 phosphorylation without affecting IκBα degradation. In unstimulated cells, the NF-κB p65/p50 heterodimer is held inactive in the cytoplasm by the inhibitory protein IκBα. Pro-inflammatory stimuli activate IKK, which in turn phosphorylates IκBα, resulting in its ubiquitination-mediated degradation, allowing the NF-κB released to enter the nucleus and activate gene expression. Thus, IκBα degradation is used widely as an indication of NF-κB activation. However, the transcriptional activity of NF-κB is also affected by post-translational modifications such as phosphorylation and acetylation, and these mechanisms are independent from IκBα degradation [33]. We found that GS12021 (20 μM) significantly inhibited the phosphorylation of p65 NF-κB at Ser536, an event required for the transactivation activity of NF-κB [34–36], but it did not prevent the degradation of IκBα stimulated by LPS. We also found that GS12021 significantly inhibited LPS-stimulated NF-κB luciferase activity only at 40 μM. Taken together, these findings suggest that GS12021 inhibits NF-κB and it has an anti-inflammatory function at high concentration, but at low concentration GS12021 may also have an anti-inflammatory role, independent of NF-κB inhibition. The present study showed that silencing of AMPKα1 expression by siRNA transfection impaired the ability of GS12021 to protect against LPS-induced mRNA expression of inflammatory genes. This finding established AMPK as a primary mediator of the anti-inflammatory actions of GS12021 on macrophages. SIRT1 was found to be dispensable for
AMPK is a multimeric serine/threonine kinase comprising α-, β-, and γ-subunits and acts as a "sensor" of the energy status of cells. A wide range of environmental stressors that cause a reduction in the ATP/AMP ratio in cells serve to activate AMPK via multiple mechanisms, including phosphorylation of the α-subunit on Thr172 by upstream kinases. Activated AMPK then "shuts-off" anabolic pathways while simultaneously activating catabolic pathways. AMPK signaling is also critical for various physiologic processes, including inflammation as well as the proliferation and death of cells. Many studies have demonstrated that activation of AMPK signaling downregulates the function of the NF-κB system [37–39]. It seems that AMPK suppresses NF-κB signaling indirectly via its downstream mediators (e.g., SIRT1, Forkhead box O family, and PPARγ co-activator 1α, which can subsequently repress the expression of inflammatory factors). GS12021 increased the expression of SIRT1, and SIRT1 is a well-established modulator of inflammation through the deacetylation and transactivation of NF-κB, but our data demonstrated that SIRT1 is not necessary for the inhibitory function of GS12021 upon inflammation. Collectively, our data suggest that a new methylhonokiol analog GS12021 activates AMPK, which mediates GS12021’s anti-inflammatory function independently of SIRT1 (Fig. 10). We have tried many ways to address the question that how AMPK mediates GS12021’s anti-inflammatory function independently of NF-κB or SIRT1 with no conclusive results. Further additional studies are required to dissect the molecular mechanism of action of GS12021.
CONCLUSION

We have identified a new 4-O-methylhonokiol analog, GS12021 and provided evidence that it exerts its anti-inflammatory effects in macrophages by activating AMPK signaling pathways. Given that there is an increasing need for safe and efficient treatment for T2DM and other chronic inflammatory diseases, our finding that GS12021 has potent anti-inflammatory effects in macrophages and adipocytes, and markedly inhibits macrophage chemotaxis in response to adipocyte-derived chemoattractants sheds light on therapies against obesity and obesity-associated insulin resistance. Further investigations of the effects of GS12021 in vivo will help to ascertain if GS12021 has therapeutic potential for obesity-linked inflammatory diseases and insulin resistance.

Supporting Information

S1 File. File contains Figures A and B. Figure A. Synthesis and structures of O-methylhonokiol derivatives. (A) Synthesis of aryl carbamate derivatives (GS12021 and c1–c5) from 4-O-methylhonokiol. (B) The structures of isoxazole derivatives (c6–c9) of 4-O-methylhonokiol.

Figure B. The effect of GS12021 on iNOS protein stability. RAW 264.7 cells were incubated with LPS (10 ng/mL) for 6 h with or without pretreatment with GS12021 (20 μM) for 0.5 h, and then exposed to cycloheximide (CHX; 5 μg/mL) from 1 h to 4 h. Representative image of western blot analyses for iNOS expression.

Acknowledgments

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2012R1A1A1014527) and the Pioneer Research Center Program through the NRF funded by the Ministry of Science, ICT & Future Planning (2014M3C1A3001556).

Author Contributions

Conceived and designed the experiments: SK JKJ SYS EJB. Performed the experiments: SK SOK YL XF. Analyzed the data: SK SOK SYS EJB. Contributed reagents/materials/analysis tools: BHP JKJ SYS EJB. Wrote the paper: SK SYS EJB.

References

1. Glass CK, Olefsky JM (2012) Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 15: 635–645. doi: 10.1016/j.cmet.2012.04.001 PMID: 22560216
2. Osborn O, Olefsky JM (2012) The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18: 363–374. doi: 10.1038/nm.2627 PMID: 22395709
3. Sartipy P, Loskutoff DJ (2003) Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 100: 7265–7270. PMID:12756299
4. Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL, et al. (2006) Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res 4: 621–633. PMID: 16966432
5. Arora S, Singh S, Piazza GA, Contreras CM, Panyam J, et al. (2012) Honokiol: a novel natural agent for cancer prevention and therapy. Curr Mol Med 12: 1244–1252. PMID: 22834627
6. Chen YJ, Tsai KS, Chan DC, Lan KC, Chen CF, et al. (2014) Honokiol, a low molecular weight natural product, prevents inflammatory response and cartilage matrix degradation in human osteoarthritis chondrocytes. J Orthop Res 32: 573–580. doi: 10.1002/jor.22577 PMID: 24375705
7. Fan S, Li X, Lin J, Chen S, Shan J, et al. (2014) Honokiol inhibits tumor necrosis factor-alpha-stimulated rat aortic smooth muscle cell proliferation via caspase- and mitochondrial-dependent apoptosis. Inflammation 37: 17–26. doi: 10.1007/s10753-013-9707-y PMID: 23933846

8. Lee YJ, Choi DY, Choi IS, Kim KH, Kim YH, et al. (2012) Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. J Neuroinflammation 9: 35. doi: 10.1186/1742-2094-9-35 PMID: 22339795

9. Oh JH, Ban JO, Cho MC, Jo M, Jung JK, et al. (2012) 4-O-methylhonokiol inhibits colon tumor growth via p21-mediated suppression of NF-kappaB activity. J Nutr Biochem 23: 706–715. doi: 10.1016/j.jnutbio.2011.03.013 PMID: 21820300

10. Zhu X, Wang Z, Hu C, Li Z, Hu J (2014) Honokiol suppresses TNF-alpha-induced migration and matrix metalloproteinase expression by blocking NF-kappaB activation via the ERK signaling pathway in rat aortic smooth muscle cells. Acta Histochem 116: 588–595. doi: 10.1016/j.acthis.2013.11.005 PMID: 24360976

11. Kim YJ, Choi MS, Cha BY, Woo JT, Park YB, et al. (2013) Long-term supplementation of honokiol and magnolol ameliorates body fat accumulation, insulin resistance, and adipose inflammation in high-fat fed mice. Mol Nutr Food Res 57: 1988–1998. doi: 10.1002/mnfr.201300113 PMID: 23901038

12. Zhang Z, Chen J, Jiang X, Wang J, Yan X, et al. (2014) The Magnolia Bioactive Constituent 4-O-Methylhonokiol Protects against High-Fat Diet-Induced Obesity and Systemic Insulin Resistance in Mice. Oxid Med Cell Longev 2014: 965954. doi: 10.1155/2014/965954 PMID: 24991305

13. Lee B, Kwak JH, Huang SW, Jang JY, Lim S, et al. (2012) Design and synthesis of 4-O-methylhonokiol analogs as inhibitors of cyclooxygenase-2 (COX-2) and PGF(1) production. Bioorg Med Chem 20: 2860–2868. doi: 10.1016/j.bmc.2012.03.026 PMID: 22494844

14. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, et al. (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142: 687–698. doi: 10.1016/j.cell.2010.07.041 PMID: 20813258

15. Matsouris D, Neels JG, Fan W, Li PP, Nguyen MT, et al. (2009) Glucocorticoids and thiazolidinediones interfere with adipocyte-mediated macrophage chemotaxis and recruitment. J Biol Chem 284: 31223–31235. doi: 10.1074/jbc.M109.041665 PMID: 19740750

16. Hardie DG (2011) AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 25: 1895–1908. doi: 10.1101/gad.174201.111 PMID: 21937710

17. Gaskin FS, Kamada K, Zuidema MY, Jones AW, Rubin LJ, et al. (2011) Isoform-selective 5'-AMP-activated protein kinase inhibitor-dependent preconditioning mechanisms to prevent posts ischemic leukocyte-endothelial cell adhesive interactions. Am J Physiol Heart Circ Physiol 300: H1352–1360. doi: 10.1152/ajpheart.00944.2010 PMID: 21239628

18. Bai A, Yong M, Ma AG, Ma Y, Weiss CR, et al. (2010) Novel anti-inflammatory action of 5-aminoimidazole-4-carboxamide ribonucleoside with protective effect in dextran sulfate sodium-induced acute and chronic colitis. J Pharmacol Exp Ther 333: 717–725. doi: 10.1124/jpet.109.164954 PMID: 20237071

19. Nagalingam A, Arbiser JL, Bonner MY, Saxena NK, Sharma D (2012) Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res 14: R35. PMID: 22353783

20. Sag D, Carling D, Stout RD, Suttles J (2008) Adenosine S’-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol 181: 8633–8641. PMID: 19050283

21. Lan F, Cacciso JM, Ruderman N, Ido Y (2008) SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 283: 27628–27635. doi: 10.1074/jbc.M805711200 PMID: 18687677

22. Yoshizaki T, Schenk S, Imamura T, Babendure JL, Sonoda N, et al. (2010) SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab 298: E419–428. doi: 10.1152/ajpendo.00417.2009 PMID: 19996381

23. Lee NJ, Oh JH, Ban JO, Shim JH, Lee HP, et al. (2013) 4-O-methylhonokiol, a PPARgamma agonist, inhibits prostate tumour growth: p21-mediated suppression of NF-kappaB activity. Br J Pharmacol 168: 1135–1145. doi: 10.1111/bjph.123812012.02235.x PMID: 23043610

24. Bossink AW, Paemen L, Jansen PM, Hack CE, Thijs LG, et al. (1995) Plasma levels of the chemokines monocyte chemotactic proteins-1 and-2 are elevated in human sepsis. Blood 86: 3841–3847. PMID: 7579352

25. Kim CS, Park HS, Kawada T, Kim JH, Lim D, et al. (2006) Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 30: 1347–1355. PMID: 16534530
26. Takahashi K, Mizuarai S, Araki H, Mashiko S, Ishihara A, et al. (2003) Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem 278: 46654–46660. PMID:13129912

27. Yoshimura T, Yuki N, Moore SK, Appella E, Lerman MI, et al. (1989) Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene J.E. FEBS Lett 244: 487–493. PMID:2465924

28. Hayashida K, Nanki T, Girschick H, Yavuz S, Ochi T, et al. (2001) Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8. Arthritis Res 3: 118–126. PMID:11178119

29. Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, et al. (2007) Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 360: 772–777. PMID:17631861

30. Takahashi M, Galligan C, Tessarollo L, Yoshimura T (2009) Monocyte chemoattractant protein-1 (MCP-1), not MCP-3, is the primary chemokine required for monocyte recruitment in mouse peritonitis induced with thioglycollate or zymosan A. J Immunol 183: 3463–3471. doi: 10.4049/jimmunol.0802812 PMID:19641140

31. Tei N, Tanaka J, Sugimoto K, Nishihara T, Nishioka R, et al. (2013) Expression of MCP-1 and fractalkine on endothelial cells and astrocytes may contribute to the invasion and migration of brain macrophages in ischemic rat brain lesions. J Neurosci Res 91: 681–693. doi: 10.1002/jnr.23202 PMID:23400803

32. Kusano KF, Nakamura K, Kusano H, Nishii N, Banba K, et al. (2004) Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis. Circ J 68: 671–676. PMID:15226634

33. Schmitz ML, Bacher S, Kracht M (2001) I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations. Trends Biochem Sci 26: 186–190. PMID:11246025

34. Duran A, Diaz-Meco MT, Moscat J (2003) Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation. EMBO J 22: 3910–3918. PMID:12881425

35. Jiang X, Takahashi N, Matsui N, Tetsuka T, Okamoto T (2003) The NF-kappa B activation in lymphotoxin beta receptor signaling depends on the phosphorylation of p65 at serine 536. J Biol Chem 278: 919–926. PMID:12419817

36. Sanchez-Valdepenas C, Punzon C, San-Antonio B, Martin AG, Fresno M (2007) Differential regulation of p65 and c-Rel NF-kappaB transactivating activity by Cot, protein kinase C zeta and NIK protein kinases in CD3/CD28 activated T cells. Cell Signal 19: 528–537. PMID:17070014

37. Yang Z, Kahn BB, Shi H, Xue BZ (2010) Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem 285: 19051–19059. doi: 10.1074/jbc.M110.123620 PMID:20421294

38. Bai A, Ma AG, Yong M, Weiss CR, Ma Y, et al. (2010) AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem Pharmacol 80: 1708–1717. doi: 10.1016/j.bcp.2010.08.009 PMID:20797389

39. Hatton Y, Akimoto K, Nishikimi T, Matsuoka H, Kasai K (2006) Activation of AMP-activated protein kinase enhances angiotensin II-induced proliferation in cardiac fibroblasts. Hypertension 47: 265–270. PMID:16380538